Search PubMed⌕ Search

Biomedical subjects

Karoline Wenzel

Publications and source records attributed to Karoline Wenzel.

5 recordsLinked to original sources
PubMed2004

Restless legs syndrome: changes of induced electroencephalographic beta oscillations-an ERD/ERS study.

STUDY OBJECTIVES: Primary or idiopathic restless legs syndrome (RLS) is a sensorimotor disorder of unknown neurophysiologic origin. SETTING AND PATIENTS: Ten patients with RLS and 10 healthy control subjects were investigated. Postmovement beta oscillations (event-related synchronization, ERS) induced by movement of the right index finger were measured by electroencephalography and analyzed. RESULTS: We found differences between patients and controls for ERS values at electrode positions C3 and Cz. At C3, the lower beta band ERS (14-20 Hz) in the RLS group was 101.2% compared with 27.5% in the control group (P < .05); in the upper beta band, (20-32 Hz) the findings were 97.8% and 29.0%, respectively, for the RLS and control groups (P < .01). At electrode Cz, no significant difference could be found in the lower beta band, but, for the upper beta band, patients showed significantly higher values than did the healthy control subjects (68.5% vs 25.6%, P < .05). CONCLUSIONS: We interpret these findings as a higher need for motor-cortical inhibition in RLS patients due to an increased level of excitation by motor-cortex activation and input from neighboring functionally interrelated cortical areas (hand and foot region). These results reveal new potentially important findings of the neurophysiologic and pathophysiologic origin of primary RLS.

Adult↗
PubMed2003

The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval.

Recently, a new locus (PARK8) for autosomal dominant parkinsonism has been identified in one large Japanese family. Linkage has been shown to a 16-cM centromeric region of chromosome 12, between markers D12S1631 and D12S339. We tested 21 white families with Parkinson disease and an inheritance pattern compatible with autosomal dominant transmission for linkage in this region. Criteria for inclusion were at least three affected individuals in more than one generation. A total of 29 markers were used to saturate the candidate region. One hundred sixty-seven family members were tested (84 affected and 83 unaffected). Under the assumption of heterogeneity and through use of an affecteds-only model, a maximum multipoint LOD score of 2.01 was achieved in the total sample, with an estimated proportion of families with linkage of 0.32. This LOD score is significant for linkage in a replication study and corresponds to a P value of.0047. Two families (family A [German Canadian] and family D [from western Nebraska]) reached significant linkage on their own, with a combined maximum multipoint LOD score of 3.33, calculated with an affecteds-only model (family A: LOD score 1.67, P=.0028; family D: LOD score 1.67, P=.0028). When a penetrance-dependent model was calculated, the combined multipoint LOD score achieved was 3.92 (family A: LOD score 1.68, P=.0027; family D: LOD score 2.24, P=.0007). On the basis of the multipoint analysis for the combined families A and D, the 1-LOD support interval suggests that the most likely disease location is between a CA repeat polymorphism on genomic clone AC025253 (44.5 Mb) and marker D12S1701 (47.7 Mb). Our data provide evidence that the PARK8 locus is responsible for the disease in a subset of families of white ancestry with autosomal dominant parkinsonism, suggesting that it could be a more common locus.

Chromosome Mapping↗
PubMed2002

Sleep attacks in patients taking dopamine agonists: review.

OBJECTIVES: To assess the evidence for the existence and prevalence of sleep attacks in patients taking dopamine agonists for Parkinson's disease, the type of drugs implicated, and strategies for prevention and treatment. DESIGN: Review of publications between July 1999 and May 2001 in which sleep attacks or narcoleptic-like attacks were discussed in patients with Parkinson's disease. RESULTS: 124 patients with sleep events were found in 20 publications. Overall, 6.6% of patients taking dopamine agonists who attended movement disorder centres had sleep events. Men were over-represented. Sleep events occurred at both high and low doses of the drugs, with different durations of treatment (0-20 years), and with or without preceding signs of tiredness. Sleep attacks are a class effect, having been found in patients taking the following dopamine agonists: levodopa (monotherapy in 8 patients), ergot agonists (apomorphine in 2 patients, bromocriptine in 13, cabergoline in 1, lisuride or piribedil in 23, pergolide in 5,) and non-ergot agonists (pramipexole in 32, ropinirole in 38). Reports suggest two distinct types of events: those of sudden onset without warning and those of slow onset with prodrome drowsiness. CONCLUSION: Insufficient data are available to provide effective guidelines for prevention and treatment of sleep events in patients taking dopamine agonists for Parkinson's disease. Prospective population based studies are needed to provide this information.

Adult↗